Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.
暂无分享,去创建一个
D. Tong | R. Zeillinger | R. Schmutzler | E. Kubista | E. Kucera | P. Speiser | C. Schneeberger | N. Concin | S. Leodolter | K. Czerwenka
[1] D. Tong,et al. Quantitative determination of gene expression by competitive reverse transcription-polymerase chain reaction in degraded RNA samples. , 1997, Analytical Biochemistry.
[2] Takuma Sasaki,et al. Inverse Correlation between mRNA Expression of Plasminogen Activator Inhibitor‐2 and Lymph Node Metastasis in Human Breast Cancer , 1996, Japanese journal of cancer research : Gann.
[3] F. Ghezzo,et al. Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer , 1995, The International journal of biological markers.
[4] L. Yamamoto,et al. Estrogen and progesterone receptor mrna levels in primary breast cancer: Association with patient survival and other clinical and tumor features , 1994, International journal of cancer.
[5] H. Heinzl,et al. pS2 protein status fails to be an independent prognostic factor in an average breast cancer population. , 1994, Anticancer research.
[6] G. Contesso,et al. Estrogen receptors (ER) in human breast cancer. The significance of a new prognostic factor based on both ER protein and ER mRNA contents , 1994, Cancer.
[7] J. Foekens,et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Elton,et al. pS2 is an independent factor of good prognosis in primary breast cancer. , 1993, British Journal of Cancer.
[9] N. Brünner,et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. , 1993, Cancer research.
[10] O. Stål,et al. Relationships of DNA ploidy, S‐phase fraction and hormone receptor status to tumor stage in breast cancers detected by population screening , 1992, International journal of cancer.
[11] J. Prud'homme,et al. Enzyme‐linked immunosorbent assay of ps2 in breast cancers, benign tumors, and normal breast tissues correlation with prognosis and adjuvant hormone therapy , 1992, Cancer.
[12] V. Kosma,et al. Hormone receptors as prognostic factors in female breast cancer. , 1991, Annals of medicine.
[13] A. Desplaces,et al. Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. , 1991, British Journal of Cancer.
[14] M. Bennett,et al. Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. , 1991, British Journal of Cancer.
[15] R. Zeillinger,et al. Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation. , 1990, Oncogene.
[16] J. Foekens,et al. Prediction of relapse and survival in breast cancer patients by pS2 protein status. , 1990, Cancer research.
[17] W. McGuire,et al. Sensitive detection of estrogen receptor RNA by polymerase chain reaction assay. , 1990, Journal of the National Cancer Institute.
[18] B. Eisenstein,et al. The polymerase chain reaction. A new method of using molecular genetics for medical diagnosis. , 1990, The New England journal of medicine.
[19] G. Contesso,et al. A new approach allowing an early prognosis in breast cancer: the ratio of estrogen receptor (ER) ligand binding activity to the ER-specific mRNA level. , 1989, Oncogene.
[20] B. Katzenellenbogen,et al. Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors. , 1989, Molecular endocrinology.
[21] G M Clark,et al. Steroid receptors and other prognostic factors in primary breast cancer. , 1988, Seminars in oncology.
[22] R. Coombes,et al. Characterization of estrogen receptor messenger RNA in human breast cancer. , 1987, Cancer research.
[23] S. Hussain,et al. The effect of tumor size and axillary lymph node metastasis on estrogen and progesterone receptors in primary breast cancer , 1986, Journal of surgical oncology.
[24] D. Lawrence,et al. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. , 1984, The Journal of biological chemistry.
[25] S. Wells,et al. Biochemical correlates of morphologic differentiation in human breast cancer. , 1982, Surgery.
[26] L. Liotta,et al. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. , 1981, Cancer research.
[27] W. Black,et al. Benign Breast Tumours , 1950, Medicine illustrated.
[28] G. Scatchard,et al. THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS , 1949 .
[29] J. Horiguchi,et al. Expression of pS2 estrogen-inducible protein in primary breast cancer. , 1996, Oncology.
[30] J. Neoptolemos,et al. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. , 1994, European journal of cancer.
[31] A. Marchese,et al. Quantitative PCR: An Overview , 1994 .
[32] R. Scheuermann,et al. Polymerase chain reaction-based mRNA quantification using an internal standard: analysis of oncogene expression. , 1993, Methods in enzymology.
[33] K. Pollow,et al. Criteria for the establishment of a double-labeling assay for simultaneous determination of estrogen and progesterone receptors. , 1984, Oncology.
[34] B. Katzenellenbogen. Dynamics of steroid hormone receptor action. , 1980, Annual review of physiology.